Indolent Non-Hodgkin Lymphoma — Trials

Indolent Non-Hodgkin Lymphoma — Trials · CancerIndex

Clinical trials

Registered studies

791 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 212
Recruiting: 104
Ph III recruiting: 4
Growth YoY: +51.7%
Industry share: 20%
Top sponsor: City of Hope Medical Center
Termination share: 36.9%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (150)

clinicaltrialsPublishedShowing 51–67 of 67 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT06390956	Pirtobrutinib in Combination With Rituximab in Adults With Untreated Marginal Zone Lymphoma (PIONEER-MZL)	recruiting	Phase 2	23	University of UtahOTHER	1	Dec 4, 2025	clinicaltrials
NCT06716658	JAK1 Inhibitor Golidocitnib for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas	recruiting	Phase 2	48	Institute of Hematology & Blood Diseases Hospital, ChinaOTHER	1	Nov 18, 2025	clinicaltrials